OvaScience Inc. (NASDAQ:OVAS) traded down 2.5% during mid-day trading on Friday . The stock traded as low as $6.28 and last traded at $6.29, with a volume of 246,873 shares. The stock had previously closed at $6.45.

A number of equities research analysts have recently weighed in on OVAS shares. JPMorgan Chase & Co. lowered their target price on OvaScience from $9.00 to $8.00 and set a “neutral” rating for the company in a research note on Friday, August 5th. JMP Securities reissued a “neutral” rating on shares of OvaScience in a research note on Wednesday, August 10th. Zacks Investment Research raised OvaScience from a “hold” rating to a “buy” rating and set a $7.00 target price for the company in a research note on Wednesday, August 10th. Leerink Swann reissued a “hold” rating and issued a $7.00 target price (up previously from $6.00) on shares of OvaScience in a research note on Sunday, May 8th. Finally, Credit Suisse Group AG reissued a “sell” rating on shares of OvaScience in a research note on Tuesday, July 12th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have assigned a buy rating to the stock. OvaScience currently has a consensus rating of “Hold” and an average price target of $10.98.

The stock’s 50-day moving average price is $5.75 and its 200 day moving average price is $7.09. The firm’s market cap is $224.75 million.

OvaScience (NASDAQ:OVAS) last issued its quarterly earnings data on Thursday, August 4th. The company reported ($0.62) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.78) by $0.16. The firm had revenue of $0.19 million for the quarter, compared to analysts’ expectations of $0.21 million. During the same quarter in the previous year, the business earned ($0.64) EPS. The company’s revenue for the quarter was up 530.0% on a year-over-year basis. Analysts forecast that OvaScience Inc. will post ($2.66) earnings per share for the current year.

OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.